HI
LCTX icon

Humankind Investments’s Lineage Cell Therapeutics LCTX Stock Holding History

Humankind Investments’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-26,737
Closed -$47K – 64
2020
Q4 		$47K Buy
+26,737
New +$37.4K 0.05% 24

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Humankind Investments's LCTX Position: Q1 2021 in Review

Humankind Investments sold out of Lineage Cell Therapeutics (LCTX) in Q1 2021, closing a stake of 26,737 shares — an estimated $47K sold.

Humankind Investments first reported a position in LCTX in Q4 2020 and held it in 1 quarter. The position peaked at $47K in Q4 2020. 102 funds tracked by Wall St. Rank hold LCTX as of Q1 2021.

  • Humankind Investments reported no remaining Lineage Cell Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Humankind Investments sold 26,737 Lineage Cell Therapeutics shares in Q1 2021, an estimated $47K.
  • Humankind Investments first reported a position in Lineage Cell Therapeutics in Q4 2020 and held it in 1 quarter.
  • Humankind Investments's Lineage Cell Therapeutics position peaked at $47K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2021.

Based on Humankind Investments's 13F filing for Q1 2021, filed 14 May 2021.